What is the price-to-earnings ratio of Biocept?
The price-earnings ratio of Biocept is currently 0.01.
Biocept P/S 2025
Biocept P/S
0.01
Ticker
BIOC
ISIN
US09072V5012
WKN
A2QEQE
As of Sep 26, 2025, Biocept's P/S ratio stood at 0.01, a 0% change from the 0.01 P/S ratio recorded in the previous year.
The Biocept P/S history
Biocept Aktienanalyse
What does Biocept do?
Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding Biocept's P/S Ratio
Biocept's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing Biocept's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating Biocept's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in Biocept’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about Biocept stock
How has the price-earnings ratio of Biocept changed compared to last year?
The price-to-earnings ratio of Biocept has increased by 0% increased compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Biocept high compared to other companies?
Yes, the price-to-earnings ratio of Biocept is high compared to other companies.
How does an increase in the price-earnings ratio of Biocept affect the company?
An increase in the price-earnings ratio of Biocept would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Biocept affect the company?
A decrease in the price-earnings ratio of Biocept would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Biocept?
Some factors that influence the price-earnings ratio of Biocept are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Biocept pay?
Over the past 12 months, Biocept paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Biocept is expected to pay a dividend of 0 USD.
What is the dividend yield of Biocept?
The current dividend yield of Biocept is .
When does Biocept pay dividends?
Biocept pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Biocept?
Biocept paid dividends every year for the past 0 years.
What is the dividend of Biocept?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Biocept located?
Biocept is assigned to the 'Health' sector.
Wann musste ich die Aktien von Biocept kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Biocept from 9/26/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/26/2025.
When did Biocept pay the last dividend?
The last dividend was paid out on 9/26/2025.
What was the dividend of Biocept in the year 2024?
In the year 2024, Biocept distributed 0 USD as dividends.
In which currency does Biocept pay out the dividend?
The dividends of Biocept are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Biocept
Our stock analysis for Biocept Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biocept Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
